MedinCell : Corporate presentation January 2020

January 14, 2020 at 06:43 am EST

BUILDING A GLOBAL PHARMA LEADER

Impact with Long-Acting Injectables

Corporate Presentation - January 2020

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

The following applies to this document, the oral presentation of the information in this document by Medincell S.A. (the "Company") or any person on behalf of the Company and any question-and-answer session that follows the oral presentation (collectively, the "Information").

We remind you that you have agreed, prior to being granted access to the Information, that: (i) you will not disclose the Information to anyone within your firm (other than and subject to the restrictions you have agreed to when your firm was initially contacted) or outside your firm, and (ii) these restrictions will apply to your entire firm. By attending the meeting where this presentation is made, or by reading this document, you further agree to be bound by the following limitations and qualifications. Failure to comply with these may constitute a violation of applicable securities laws.

The Information is delivered to you on the basis of your compliance with the legal and regulatory obligations to which you are subject. Copies of this document must be returned at the end of the meeting. This document may not be removed from the premises.

If this document has been received in error, it must be immediately returned, along with any other copies, to the Company. The Information is made available on a confidential basis, to a limited number of recipients solely for the purposes of preliminary discussions regarding a potential initial public offering of the Company (the "Proposed Transaction"). The Information, including this presentation and its contents, has not been verified by Bryan Garnier or Crédit Agricole CIB (the "Banks"), or any of their affiliates, shareholders, directors, officers, advisers, employees and representatives or otherwise independently verified.

Some of the financial information contained in this document has been prepared in accordance with French GAAP. French GAAP differ from International Financial Reporting Standards (IFRS); related financial information is therefore not directly comparable. In addition, some of the financial information contained in this document is not directly extracted from the Company's accounting systems or records and is not IFRS accounting measures; it has not been independently reviewed or verified by the Company's auditors or by the Banks.

The market data and certain industry forecasts included in this document were obtained from internal surveys, estimates, reports and studies, where appropriate, as well as external market research, publicly available information and industry publications. The Company, the Banks, their affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry. Such data and forecasts are included herein for information purposes only.

This document contains certain statements that are forward-looking. These statements refer in particular to the Company management's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and

contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. The Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice.

No representation or warranty, express or implied, is made as to, and no reliance should be placed upon, the fairness, accuracy, completeness or correctness of the Information and none of the Company, the Banks, their affiliates, shareholders, directors, advisors, employees and representatives accept any responsibility in this respect.

The Information does not constitute a recommendation regarding the Proposed Transaction and does not purport to contain all information that may be required to evaluate the Proposed Transaction. The merit and suitability of an investment in the Company should be independently

evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment. Investors should not subscribe for or purchase any securities of the Company except on the basis of information in a final form prospectus that may be published by the Company, which would supersede this presentation in its entirety and would contain a description of risk factors pertaining to the Company, its businesses and such an investment. In accepting the Information the recipient acknowledges that it makes all trading and investment decisions in reliance on its own judgment and not in reliance on any of the Company, the Banks, their affiliates, shareholders, directors, officers, advisers, employees or representatives.

The Banks are acting solely for the Company in connection with the Proposed Transaction and no one else. They will not regard any other person (whether or not a recipient of the Information) as a client in relation to the Proposed Transaction and, accordingly, will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person in relation to the contents of the Information or in connection with the Proposed Transaction.

The Information does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, the United Kingdom, the United States or any other jurisdiction. It does not constitute any form of commitment on the part of the Company or any other person. Neither the Information nor any other written or oral information made available to any recipient or its advisers will form the basis of any contract or commitment whatsoever. In particular, in furnishing the Information, the Company, the Banks, their affiliates, shareholders, directors, officers, advisers employees or representatives undertake no obligation to provide the recipient with access to any additional information. In the European Economic Area ("EEA") the Information is only addressed to and directed at persons in member states who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) ("Qualified Investors").

Within the United Kingdom, the Information is intended for distribution only to persons who are Qualified Investors who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order

2005, as amended (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order or (iii) are persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons") and in such a case any investment or investment activity to which the Information relates is available only to relevant persons and will be engaged in only with relevant persons.

Securities may not be offered, subscribed or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. The securities of the Company have not been and will not be registered under the U.S. Securities Act and the Company does not intend to make a public offer of its securities in the United States. Neither this document nor any copy of it may be taken or transmitted into, directly or indirectly, into the United States, other than to "qualified institutional buyers", within the meaning of Rule 144A under the Securities Act.

Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or to any person in any of those jurisdictions.

P2 •

INVESTMENT HIGHLIGHTS

Most advanced product in clinical phase 3
Tier 1 partnerships > Teva Pharmaceuticals and the Bill & Melinda Gates Foundation
Products based on approved APIs and 505(b)2
Polymerjoint-venture with Corbion (Amsterdam: CRBN)> GMP polymers available at commercial scale

PORTFOLIO

(as of January 1st, 2020)

IND / IMPD

Approval for Human Clinical Trials

		mdc-TJK	mdc-CWM	mdc-IRM
Next potential candidates for preclinical & IND/IMPD	Antipsychotic	Pain & inflammation (opioid free)	Schizophrenia
> 7 products in formulation and preclinical		Subcutaneous injection	Intraarticular injection	Subcutaneous injection
		Partner: Teva pharmaceuticals	Partner: Arthritis Innovation Corporation	Partner: Teva pharmaceuticals

Formulation	Preclinical	Clinical phase 1	Clinical phase 2	Clinical phase 3	NDA / Market

P3 •

LAST 12-MONTH NEWSFLOW & CASH POSITION

Press releases are available on invest.medincell.com

Clinical newsflow				FDA IND clearance to initiate	mdc-CWM		Start of first in human
			clinical activities of mdc-TJK	progresses as planned	for mdc-TJK

2019
January	February	March	April	May	June	July	August	September	October	November	December

In vivo demonstration of the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management

Funding from the Gates Foundation for the second formulation phase of a 6-month injectable contraceptive

7,5 M€	New grant from
from the	the Gates Foundation for
European	feasibility study for HIV PrEP
Investment Bank
mdc-ANG enters	New US partner to address	Additional $19 M grant
preclinical development	untapped financial potential	from the Bill & Melinda Gates
	in Animal Health	Foundation for mdc-WWM

MedinCell - January 2020

Cash position

as of September 30, 2019

16,1 M€ in cash and cash equivalents
0,7 M€ inshort-term investments
3,9 M€ innon-current financial assets
5 M€ drawable from the European Investment Bank loan under conditions

Note: $4.9 million upfront out of $19 million received in November 2019 from the Gates Foundation

P4 •

CLINICAL UPCOMING DEVELOPMENT NEWSFLOW

As programs based on MedinCell's technology move into more advanced phases, data, analysis and conclusions may only be communicated on an ad hoc basis to preserve clinical study integrity and competitive positioning

Program

Current status

Next potential milestone

mdc-IRM

Partner: Teva pharmaceuticals

Phase 3

multicenter, randomized,double-blind,placebo-controlled study to evaluate the efficacy, safety, and tolerability of risperidone
extended-release injectable suspension for subcutaneous use as maintenance treatment in adult and adolescent patients with schizophrenia

Location: United States

Start date: April 2018

Estimated enrollment: 596 participants

Primary endpoint : Time to impending relapse

Estimated completion date: H2 2020

> US Phase 3 interim analysis >H2 2020

Program

Current status

Next potential milestone

mdc-CWM

Partner: Arthritis Innovation Corporation

Phase 2

Phase 2, randomized,single-blind,active-control, parallel group study to evaluate safety and activity of a single administration of celecoxib for management of postoperative pain in participants undergoing unilateral total knee replacement (TKR)

Location: United States

Start date: May 2018

Enrollment: 20 participants

Primary endpoints : pain measures and post- surgical opioid consumption

Primary completion date: Summer 2020

> US Phase 2 completion >H1 2020

Program		Current status	Next potential milestone
	Phase 1	Location: United States
mdc-TJK
Start date: Q4 2019	> US Phase 1 results > 2021
Partner: Teva pharmaceuticals	Safety study
Primary endpoints : Safety

P5 •

NEXT POTENTIAL CANDIDATES FOR PRECLINICAL & IND

7 PRODUCTS IN FORMULATION AND PRECLINICAL
SUBCUTANEOUS INJECTION

PROGRAM	PARTNER / INTERNAL	CURRENT STATUS	INDICATION	MOLECULE	MAIN TARGETED IMPACT

mdc-ANG	Partner:	Preclinical	Antipsychotic	confidential	Adherence
	Teva Pharmaceuticals

mdc-GRT	MedinCell program	Formulation	Organ transplant	Tacrolimus	Adherence

mdc-WWM	Partner:	Formulation	Women's contraception	Progestin molecule	Large access to best-in-class
	the Bill & Melinda Gates Foundation			(non-MPA)	women's contraceptive

mdc-KPT	Partner:	Formulation	Pain	Confidential	Duration
(Animal Health)	Cornerstone Animal Health

Animal Health offers an attractive risk profile as the products can be tested in the target species during the lead formulation selection. Development times are significantly shorter and funding requirements may be one order of magnitude lower compared to human health products.

mdc-STG

MedinCell program

Formulation

Confidential

> PERINEURAL INJECTION

PROGRAM	PARTNER / INTERNAL	CURRENT STATUS	INDICATION	MOLECULE	MAIN TARGETED IMPACT

mdc-CMV	MedinCell program	Preclinical	Anesthesia & pain	Ropivacain	Opioid free
			(opioid free)

mdc-NVA	MedinCell program	Formulation	Chronic pain	Ropivacain	Opioid free
			(opioid free)

P6 •

BEPO®: LAI CUTTING EDGE POLYMER TECHNOLOGY

Formulation	Subcutaneous	Controlled release
		or local injection
Polymers customized formulation for each	In situ depot precipitates immediately	API is released as depot fully degrades
indication	after subcutaneous or local injection
•	PEG/PLA
•	Hydrophilic solvent
•	Active pharmaceuticals Ingredient

P7 •

WE APPLY OUR LAI TECHNOLOGY BEPO®TO MAKE DRUGS EFFICIENT

DRUG LEVEL

Time impact

known approved API
same indication

TOXICITY LEVEL

LAI

Controlled and customized release for days, weeks or months

THERAPEUTIC LEVEL

TIME

Space impact

> known approved API > new indication

P8 •

WE APPLY OUR LAI TECHNOLOGY BEPO®TO ALREADY KNOWN APPROVED APIs

Attractive risk / return profile

Simpler regulatory pathways e.g. US 505(b)(2) Significantly less financial resources needed

Significantly less risk in clinical phases especially when same original indication

HIGH

NCE	LAIs
(New Chemical Entity)	with approved APIs

RETURN

GENERIC

LOW

HIGH

SUCCESS RATE

P9 •

Portfolio

3 products in clinical trials

IND / IMPD

Approval for Human Clinical Trials

		mdc-TJK	mdc-CWM	mdc-IRM
		Antipsychotic	Pain & inflammation (opioid free)	Schizophrenia
		Subcutaneous injection	Intraarticular injection	Subcutaneous injection
		Partner: Teva pharmaceuticals	Partner: Arthritis Innovation Corporation	Partner: Teva pharmaceuticals

Formulation	Preclinical	Clinical phase 1	Clinical phase 2	Clinical phase 3	NDA / Market
					P10 •

Portfolio

3 products in clinical development

mdc-IRM

SUBCUTANEOUS RISPERIDONE

First long-acting injectable antipsychotic with Teva Pharmaceuticals

Maintenance treatment of schizophrenia

Current status: US Phase 3 (efficacy, safety and tolerability) - Initiated Q2 2018 - 596 patients

All development costs covered by Teva Pharmaceutical

		IND / IMPD
	Approval for Human Clinical Trials
				mdc-IRM
				Schizophrenia
2020				Subcutaneous injection
	Completed	Exempted	Partner: Teva pharmaceuticals
	5O5(b)2
-January
Preclinical	Clinical phase 1	Clinical phase 2	Clinical phase 3	NDA / Market
Formulation
© MedinCell					P11 •

Portfolio

3 products in clinical development

mdc-IRM

SUBCUTANEOUS RISPERIDONE

> SCHIZOPHRENIA: A CHRONIC PSYCHOSIS AFFECTING 1% OF POPULATION WW

An extremely debilitating	Positive symptoms: hallucinations, disorganized speech, delusions
disease	Negative symptoms: flat affect, poverty of speech

	Cognitive symptoms: attention, memory, executive functions

Nonadherence to	74% of patientshad discontinued medication within 18 months due to insufficient efficacy, intolerable side
prescribed treatments	effects or for other reasons(Lieberman J. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223)

Schizophrenia in the US	Schizophrenia accounts for 20% of all hospital bed-daysand over 50% of all psychiatric beds1
	Annual cost:between $134 and $174 billion per year2
	$38 billion for excess direct health care costs
	Hospital inpatient treatment, outpatient and emergency department visits, medications
	$9 billion for direct non-health care costs
	Law enforcement, incarceration, homeless shelters
	$117 billion for indirect costs
	Unemployment, lost productivity, premature mortality
	Sources: 1Comprehensive understanding of schizophrenia and its treatment, Maguire GA. Am J Health Syst Pharm. 2002 ; 2Analysis Group, Otsuka, Lundbeck LLC - 2016
	P12 •

Portfolio

3 products in clinical development

mdc-IRM

SUBCUTANEOUS RISPERIDONE

> ATYPICAL ANTIPSYCHOTICS LAIs: A $5.2 BILLION MARKET GROWING +20% CAGR (7 Major Markets)

Global atypical antipsychotics sales			LAI atypical antipsychotics sales	Global atypical
						$ billion - 7 MM - 2018								$ billion - 7MM - 2018		antipsychotics patients
				17,4																				5.2	7MM - 2016
15,9		15,4	16,2

					13,3					13,5								4.3	Japan

													12,6
																						3.6	EU	11%

																						2.9
																				2.6
																			2.2
																		1.7

																										US

																	5,2
															4,3
													3,6
						2,6			2,9													89%
		2,2
1,7


2012	2013	2014	2015		2016	2017	2018	2012	2013	2014	2015	2016	2017	2018
					LAI				Oral				Total				US		EU5		JAPAN

Oral LAI

5-year LAIs CAGR

20%

Source: IMS Sales date, Midas & Globaldata

USAis largest market:

77%of sales

Fastest Growth (+25% CAGR)

LAIsaccount for only

11% of patients

P13 •

Portfolio

3 products in clinical development

mdc-TJK

SUBCUTANEOUS ANTIPSYCHOTIC

Second long-acting injectable antipsychotic with Teva Pharmaceuticals API: confidential

Current status: US Phase 1 (safety) - Initiated Q4 2019 All development costs covered by Teva Pharmaceuticals

IND / IMPD

Approval for Human Clinical Trials

mdc-TJK

Antipsychotic

Subcutaneous injection

Partner: Teva pharmaceuticals

Formulation

Preclinical

Clinical phase 1

Clinical phase 2

Clinical phase 3

NDA / Market

P14 •

TEVA COLLABORATION

> 3 ANTIPSYCHOTICS

All development costs covered by TEVA

MedinCell receives

FTE remuneration in formulation
Development and commercial milestones of up to $122m for each product ($366m total)
Royalties on sales

Press release - Dec. 3, 2019

Teva update on the three antipsychotic products

Clinical activities begin for Second Long-acting Injectable Antipsychotic mdc-TJK. The first-inhuman study for the investigational long-acting injectable antipsychotic mdc-TJK has now commenced. The results of this study, expected during 2021, will inform future development. mdc-TJK is one of three antipsychotic products in development by the partner Teva Pharmaceuticals based on MedinCell's technology.

The phase 3 clinical trials for the lead asset, mdc-IRM, are ongoing with an interim analysis in the second half of 2020 contingent upon the projected recruitment rate and patient relapse events.

Non-clinical work on the third investigational product, mdc-ANG, continues to progress and will inform a decision on further development expected in the second half of 2020.

FTE remuneration			Development milestones		Commercial milestones
			& royalties

			IND / IMPD
		Approval for Human Clinical Trials
			mdc-TJK		mdc-IRM
			Antipsychotic		Schizophrenia
2020	Subcutaneous injection	Subcutaneous injection		Subcutaneous injection
Partner: Teva pharmaceuticals		Partner: Teva pharmaceuticals
•	mdc-ANG
-January		(Partner: Teva pharmaceuticals)
	Preclinical	Clinical phase 1	Clinical phase 2	Clinical phase 3	NDA / Market
Formulation
© MedinCell						P15 •

Portfolio

3 products in clinical development

mdc-CWM

INTRA-ARTICULAR CELECOXIB INJECTION

Collaboration with AIC

Total Knee Replacement (TKR) post-operative pain and inflammation treatment

Current status: US Phase 2 (safety and activity) - Initiated Q4 2019 Clinical development cost borne by AIC

IND / IMPD

Press release - September 20, 2019

MedinCell announces that mdc-CWMprogresses as planned

MedinCell's CEO Christophe Douat states: "We are happy to report that the mdc-CWM program, partnered and in phase 2 clinical trial, is progressing well and on schedule."

As a reminder, recruitment was capped by MedinCell's partner at 20 patients for the active phase 2 clinical study in April 2019. All participants have completed their 3-monthfollow-up visit this summer. The analysis of the data is being completed by our partner and its subcontracted clinical research organization. 12-month trial completion is scheduled on March 2020. Our partner plans to meet with FDA in the meantime to discuss the current findings and how to progress in the next trial moving forward.

The product is for management of postoperative pain in participants undergoing unilateral total knee replacement. The study's primary endpoints include pain measures and post-surgical opioid consumption.

MedinCell's CEO Christophe Douat adds: "While total knee replacement surgery leads to decreased pain in most patients, a sizable minority continue to experience severe pain and consume opioids chronically after it. It is one of the surgeries were patients use the most opioids and an estimated 15 % of these, or 150 000 patients per year, become new persistent opioid users for many months after surgery. A decrease in pain and opioid consumption should be viewed as a very positive factor in the current opioid crisis, which is one of the highest priorities of the FDA."

Approval for Human Clinical Trials

			mdc-CWM
			Antipsychotic
			Subcutaneous injection
		Exempted	Partner: Teva pharmaceuticals
		5O5(b)2

Formulation	Preclinical	Clinical phase 1	Clinical phase 2	Clinical phase 3	NDA / Market

P16 •

Portfolio

3 products in clinical development

		1.5M
mdc-CWM	0.7M
2010	2030forecast
INTRA-ARTICULAR CELECOXIB INJECTION

NUMBER OF TKR PROCEDURES IN THE US

Source: GlobalData, Orthopedic Devices [Knee Reconstruction] Market, United States, 2009-2023, Absolute Units, 2017

> A STRONG MARKET OPPORTUNITY

Unsatisfying

post-surgery pain treatment

Significant pain for two weeks and reduced but continued pain for 6-12 weeks post surgery Contraindication of traditional oral anti-inflammatory products post surgery

Effectiveness of current practices for postoperative pain management remains limited: 57% to 73% of operated patients report moderate to extreme postoperative pain, leading to longer hospitalization stay, revision surgery,

disability leave, etc.

Source: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160

Opioids epidemic issue	15.2% of TKR patients become long-term opioid users
	Source: 2018 Choices Matter Survey - Exposing a silent gateway to persistent opioid use
	The use of opioids in the treatment of postoperative pain is globally widespread and particularly in the US: c. 90%
	of operated patients
	Negative side effects observed in 96% of operated patients, increasing the duration of hospitalization in 55% of
	cases
	130 people die every day in the US because of opioids overdose according to the CDC
	Sources: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160 ; sler ER, Shah M,
	Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: Opioid-related adverse events and their impact on clinical and economic
	outcomes. Pharmacotherapy. 2013;33
	P17 •

Portfolio

3 products in clinical development

mdc-CWM

INTRA-ARTICULAR CELECOXIB INJECTION

> PRODUCT DETAILS

Molecule	Celecoxib, approved by the FDA in the pain treatment in 1998 often
	used in the treatment of acute pain, rheumatoid arthritis, ankylosing
	spondylitis etc.

Duration	Up to three months

Mechanism of	One-time local delivery for the control of post-total knee replacement
action	pain and inflammation through sustained release of Celecoxib in the
	intraarticular space, with improved safety (better cardio and
	gastrointestinal-toxicity profiles)
	Little to no systemic exposure avoids risk of adverse NSAID issues

Partner	AIC (Arthritis Innovation Corporation):

deal metricsCompany founded by North American physicians & entrepreneurs All development costs borne by AIC
50-50 profit sharing

PGE2 concentration in the synovial fluid with and without mdc-CWM

	2 500			Control
	2 000
(pg/ml)			mdc-CWM

1 500

PGE2	1 000
500

	0
	0	30	60	90

Time (days)

Data represents means, Day 0, n=35, Day 7, n=5, 4 for F14, Control; Day 30 & 90, n=5

Pre-clinical in vivo tests demonstrated efficacy, reducing PGE2 concentration for up to 3 months

P18 •

Collaboration with the

Bill & Melinda Gates Foundation

Collaboration with the Bill & Melinda Gates Foundation

> ADDRESSING MAJOR CHALLENGES OF FAMILY PLANNING WORLDWIDE

Press release - November 28, 2019

MedinCell receives $19 million grant for its mdc-WWM program

French company MedinCell and the Bill & Melinda Gates Foundation have signed an agreement for up to an additional $19 million to be granted over four years. It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover the costs that will be incurred by the project. Depending on the options chosen and on the advancement of the program, up to $11.75 million could be raised over the next 12 months including a first tranche of $4.75 million to be paid immediately. The additional $7.25 million may be collected later.

As a reminder, a previous grant of $3.5 million was awarded in November 2017 by the Gates Foundation to fund the formulation research phase. Full results should make it possible to select the candidate formulation.

MedinCell owns all marketing rights of the product worldwide, including the United States where the contraceptive market totaled more than $5 billion in 2018. Long-acting reversible contraceptives (LARC) alone (primarily solid implants and intrauterine devices) represented 28% of this market - more than $1.4 billion - with a 5-year CAGR at 7.8%. The mdc-WWM product could capture a significant share of this LARC market and even expand it easing the adoption of this type of contraception1.

In accordance with the Global Access strategy of both partners and to ensure a significant impact on women's lives, the objective is to make the product widely available. Affordable pricing in emerging economies will help eliminate cost as a barrier to increased availability and voluntary access to the product. High demand among women and girls for long-acting contraceptive options illustrate the potential for market growth and measurably improving maternal, newborn and child health. The Gates Foundation also has a non-exclusive license for non-commercial market in low- and middle-income countries.

> EXPLORATORY WORK IN HIV PrEP

Press release - November 28, 2019

MedinCell receives $19 million grant for its mdc-WWM program

Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. However, lack of adherence to an oral PrEP regime undermines its effectiveness. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of prevention after a single subcutaneous injection. The support of the Bill & Melinda Gates Foundation aims to confirm the feasibility of the product and to initiate the design of a lead formulation that could rapidly enter investigational development.

P20 •

Collaboration with the Bill & Melinda Gates Foundation

> mdc-WWM:6-MONTH SUBCUTANEOUS CONTRACEPTIVE

December 2017

$3.5 million grant

to fund the formulation of the product

November 2019

Up to $19 million additional grant

over four years to fund preclinical activities and phase 1 clinical trial. The grant is structured in advanced installments to cover the costs that will be incurred by the project

The challenge of familyAn estimated74 million women fall pregnant unintentionally every year leading to25 million unsafe abortions

planning worldwideand47,000 maternal deaths (WHO - Oct. 2019)

Best-in-classproductmdc-WWM could be the first contraceptive to combine the following essential features to make it a best-in-class product worldwide: progestin molecule (non-MPA),6-month duration, subcutaneous injection, full bio resorption, affordability

> MEDINCELL OWNS THE COMMERCIAL RIGHTS WORLDWIDE, ESP. IN THE US

US contraceptive market	> $5 billion
in 2018

Long-acting reversible	> 28% of the US market
contraceptives - LARC	> $1.4 billion
(primarily solid implants and
> 5-year CAGR at 7.8%
intrauterine devices)

mdc-WWM product could capture a significant share of this LARC market and expand it by easing the adoption of this type of contraception

Source: IQVIA

P21 •

Impact company

WE CONTRIBUTE TO SOLVING GLOBAL HEALTH CHALLENGES

Compliance & access are key issues in developing world
- WHO estimates thatone patient in two does not start or does not continue to follow their treatment and thatadherence improvement would have a greater impact than any improvement in specific
  medical treatments(World Health Organization: Adherence to Long-Term Therapies, Evidence for Actions - 2003)
- LAI can impact both compliance and access issues
Affordability should allow to tap profitability reservoir on developing countries
- Much higher volumes will counter balance pricing
- Low COGS technology
Pharmaceutical residues becoming a major environmental challenge
- Up to 95% less APIs required for a same treatment
- 1/3 of US presription become waste

(MedinCell estimates on potential positive impact of BEPO)

P23 •

A XXIstCENTURY PHARMA COMPANY MODEL

"Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives."

"Raison d'etre"̂of MedinCell voted by the General Assembly in September 2019

25 nationalities out of 130 employees
100% of MedinCell employees are shareholders or soon to be

Employee share ownership is promoted through adapted tools that guarantee alignment of the interests of employees and other shareholders. It enables a fair sharing of the value created and a balanced relationship between management and all employees

Reduced salary gaps
Collective bonus linked to product progress

P24 •

KEY FINANCIALS

	€ million	6-Month period	6-Month period
		September 30, 2019	September 30, 2018

	Revenue	3.9	1.8
	Operating result	(8.1)	(6.6)
	Net result	(9.0)	(9.8)
	Earning per share (€)	(0.45)	(0.68)
	Cash position	16.1*	11.4**
	* not including 0.7 M€ in short-term investments, 3.9 M€ in non-current financial
	assets and 5 M€ drawable under conditions from the European Investment Bank loan
2020	** not including 4.6 M€ in short-term investments and non-current financial assets
© MedinCell - January

Employees, Consultants	Nguyen Family*
and Affiliates
16%	21%

Former employees

and Affiliates

30%

Other

33%

*Anh Nguyen, Chairman of MedinCell

Market Cap: c. 140 M€

outstanding shares: 20.1 M

ISIN: FR0004065605

P26 •

Attachments

Original document
Permalink

Disclaimer

Medincell SA published this content on 14 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2020 11:42:01 UTC

Real-time Euronext Paris Other stock markets 03:15:06 2024-04-25 am EDT			5-day change	1st Jan Change
12.36 ^EUR	+2.15%		+13.94%	+72.50%

Apr. 17	Medincell: share price rises following agreement with AbbVie	CF
Apr. 16	Medincell, AbbVie to Co-Develop Injectable Therapeutics	DJ

Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	Apr. 16	CI
Medincell: Unitaid grant to combat malaria	Apr. 09	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	Apr. 09	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	Mar. 15	CI
MedinCell: new Chairman of the Supervisory Board	Mar. 14	CF
Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board	Mar. 13	CI
MedinCell: departure of Chairman of the Supervisory Board	Feb. 19	CF
Biopharmaceutical Company MedinCell Chairman Exits	Feb. 19	MT
MedinCell Announces Chairman Changes	Feb. 19	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	Jan. 09	CI
MedinCell: share price continues to rise, Jefferies to buy	Jan. 05	CF
MedinCell: first-half net loss reduced	Dec. 20	CF
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	Dec. 19	CI
MedinCell: collaboration between Teva and Royalty Pharma	Nov. 13	CF
MedinCell and European Investment Bank Sign an Amendment to the Loan Agreement	23-10-03	CI
Correction: MedinCell Completes Patient Recruitment for Late-stage Trial of Pain Relief Drug	23-08-31	MT
MedinCell Completes Patient Recruitment for Late-stage Trial of Pain Relief Drug	23-08-31	MT
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement	23-08-30	CI
MedinCell: positive initial feedback from Teva in the USA	23-08-03	CF
MedinCell Secures EUR10 Million Final Loan Tranche from European Investment Bank	23-08-01	MT
MedinCell: receives final tranche of EIB loan	23-07-31	CF
Transcript : MedinCell S.A., 2023 Earnings Call, Jun 26, 2023	23-06-26
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-26	CI

	1st Jan change	Capi.
MEDINCELL S.A.	+72.50%	372M
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+25.87%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+7.09%	219B
ROCHE HOLDING AG	-9.12%	196B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

MedinCell S.A.

Equities

MEDCL

FR0004065605

Pharmaceuticals

MedinCell : Corporate presentation January 2020

Latest news about MedinCell S.A.

Chart MedinCell S.A.

Company Profile

Income Statement Evolution

Ratings for MedinCell S.A.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals